UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/080,043	02/22/2002	Oliver Yoa-Pu Hu	26193-167918	8602

38598 7590 10/11/2006

ANDREWS KURTH LLP
1350 I STREET, N.W.
SUITE 1100
WASHINGTON, DC 20005

EXAMINER	
SPIVACK, PHYLLIS G	
ART UNIT	**PAPER NUMBER**
1614	

DATE MAILED: 10/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

October 11, 2006

VENABLE, LLP
P.O. BOX 34385
WASHINGTON, DC 20043-9998
US

Dear Sir/Madam,

Your refund request for 10/080043 in the amount of $111.00 has been denied.

There was no overpayment made by applicant. All fees were calculated and assessed properly. The fees were charged to the desposit account on the document at the time of submission although the fee was not deducted from the account until November 2005.

Sincerely,

Deborah E. Dotson
Technical Center 1600
571 272 0520

FILE COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

October 11, 2006

VENABLE, LLP
P.O. BOX 34385
WASHINGTON, DC 20043-9998
US

Dear Sir/Madam,

Your refund request for 10/080043 in the amount of $111.00 has been denied.

There was no overpayment made by applicant. All fees were calculated and assessed properly. The fees were charged to the desposit account on the document at the time of submission although the fee was not deducted from the account until November 2005.

Sincerely,

Deborah E. Dotson
Technical Center 1600
571 272 0520

– CALL Attorney

ATTENTION ATTENTION ATTENTION

Method of Refund:

- ☐ ACH/EFT
- ☐ Credit Card
- ☒ Deposit Account # 22-2061
- ☐ Treasury Check

Patent/TM/App/Serial # 10,080,043

Program Area Tech Center 1614

Date Processed 10-2-06

ATTENTION ATTENTION ATTENTION

DEP&REF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hu et al.

Appln. No. 10/080,043

Confirmation No. 8602

Filed: 22 February 2002

For: CYTOCHROME P450 3A INHIBITORS AND ENHANCERS

Art Unit: 1614

Examiner: Phyllis G. Spivack

Atty. Docket No. 39297-174169

Customer No.
26694
PATENT TRADEMARK OFFICE

REQUEST FOR REFUND

Commissioner for Patents
Attention: MAIL STOP – REFUNDS
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a request for a refund of filing fees, in the amount of $111.00 (extra claims fees), that the PTO charged to our Deposit Account No. 22-0261 on November 7, 2005. This charge was in error because this file was transferred to another firm in September 2004, and the attorney of record was not authorized to charge on the referenced deposit account at the time the fees were paid. Attached is a copy of the PTO's November 2005 Deposit Account Statement to our firm, highlighting the two charges in question. We do not have any files for this matter and so cannot verify any of the information.

It is respectfully requested that the filing fee, totaling $111.00, which was charged to this firm's Deposit Account No. 22-2061 on November 7, 2005, be refunded by crediting that amount back to our Deposit Account.

Respectfully submitted,

Date: 9/25/06

Michael A. Gollin
Registration No. 31,957
VENABLE LLP
P.O. Box 34385
Washington, D.C. 20043-9998
Phone: (202) 344-4000
FAX: (202) 344-8300

MAG/sgs
DC2/775293

Therefore, please request a refund [illegible]

Deposit Account Statement - Microsoft Internet Explorer provided by Venable LLP

https://ramps.uspto.gov/eram/Controller;jsessionid=ramps-10300-1cd4%3A436f2d85%3Ae32a42ded7391d2a

11/04	238	11264026	39509-223477	1011	$300.00	$62,525.02
11/04	239	11264026	39509-223477	1111	$500.00	$62,025.02
11/04	240	11264026	39509-223477	1311	$200.00	$61,825.02
11/04	292	11265244	58053-223306	2011	$150.00	$61,675.02
11/04	293	11265244	58053-223306	2111	$250.00	$61,425.02
11/04	294	11265244	58053-223306	2311	$100.00	$61,325.02
11/04	295	11265244	58053-223306	2201	$300.00	$61,025.02
11/04	296	11265244	58053-223306	2202	$525.00	$60,500.02
11/04	531	78746672	38793-225142	7007	$275.00	$60,225.02
11/04	671	76480103	BECAUSE SOAP WORKS	7004	$150.00	$60,075.02
11/04	1382	78747118	41577-225377	7001	$325.00	$59,750.02
11/07	1	6382042		1551	$900.00	$58,850.02
11/07	3	6798526		1562	$2,300.00	$56,550.02
11/07	5	10080043	39297-174169	2202	$27.00	$56,523.02
11/07	8	10080043	39297-174169	2201	$84.00	$56,439.02
11/07	6	6384087		1551	$900.00	$55,539.02
11/07	9	76581828	19115-202167	6001	-$375.00	$55,914.02
11/07	59	29235826	32405-220144	2012	$100.00	$55,814.02
11/07	60	29235826	32405-220144	2112	$50.00	$55,764.02
11/07	61	29235826	32405-220144	2312	$65.00	$55,699.02
11/07	62	29235826	32405-220144	2051	$65.00	$55,634.02

Marc C. Roberts
Financial Coordinator - Technology Division
Venable LLP
575 7th Street, NW
Washington, DC 20004-1601
Tel.: (202) 344-8122 Direct
Fax: (202) 344-8300
http://www.venable.com
Email: mcroberts@venable.com

PTO/SB/17 (10-02)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it displays a valid OMB control number.

164

RECEIVED
OCT 06 2003
TECH CENTER 1600/2900

PTO JC100 SEP 29 2003 PATENT & TRADEMARK OFFICE

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT ($) 55

Complete if Known	
Application Number	10/080,043
Filing Date	February 22, 2002
First Named Inventor	Oliver Yoa-Pu HU et al.
Examiner Name	James H. Reamer
Group / Art Unit	1614
Attorney Docket No.	39297-174169

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account:

Deposit Account Number: 22-0261

Deposit Account Name: VENABLE ATTORNEYS AT LAW

The Commissioner is authorized to: *(check all that apply)*
☐ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) under 1.16 or 1.17 during pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) ($) 0

2. EXTRA CLAIM FEES

			Extra Claims		Fee from below		Fee Paid
Total Claims	19	-20** =	0	X		=	0
Independent Claims	1	-3** =	0	X		=	0
Multiple Dependent				X		=	0

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) ($) 0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing request for ex parte reexam	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	55
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive – unavoidable	
1453	1,300	2453	650	Petition to revive – unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) ____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) ($) 55

SUBMITTED BY				Complete *(if applicable)*	
Name (Print/Type)	Fei-Fei Chao, Ph.D.	*Registration No. Attorney/Agent*	43,538	*Telephone*	202-344-8011
Signature	Fei-Fei Chao			*Date*	September 29, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.
SEND TO: Commissioner for Patents, Washington, DC 20231.

VENABLE ATTORNEYS AT LAW

PC Docs No. DCDocs2/487608

RAM Fee History Query

Revenue Accounting and Management

Name/Number: 10080043 Total Records Found: 8

Start Date: Any Date End Date: Any Date

Accounting Date	Sequence Num.	Fee Type	Fee Code	Fee Amount	Mailroom Date	Payment Method
04/26/2006	00000197	1	2251	$60.00	04/25/2006	DA 502518
04/26/2006	00000198	1	2814	$65.00	04/25/2006	DA 502518
11/07/2005	00000005	1	2202	$27.00	09/29/2003	DA 220261 3
11/07/2005	00000006	1	2201	$84.00	09/29/2003	DA 220261 2
10/27/2005	00000054	1	2253	$510.00	10/25/2005	DA 502518
10/02/2003	00000121	1	2251	$55.00	09/29/2003	CK
02/28/2002	00000039	1	201	$370.00	02/22/2002	CK
02/28/2002	00000040	1	581	$40.00	02/22/2002	CK

Sale List

Search by

- Accounting Date: (MMDDYY)
- Operator ID:
- Sequence No.: [ ]
- Accounting Date Start: End:
- Name/Number: 10080043
- Attrny Docket No:

Find...

ing	Operator ID	Seq No.	Sts	Name/Number	Attorney Docket	Dep Act Charge	Other Paymen
6	NNGUYEN1	110	A	10080043	39297-174169	$125.00	
5	FPATTERS	5	A	10080043	39297-174169	$111.00	
5	MDAMTE1	22	A	10080043	39297-174169	$510.00	
3	EFLORES	91	A	10080043	39297-174169		$55.(
2	SMINASS1	19	A	10080043	39297-174169		$410.(

Select | Cancel | Print Screen | Display Payment | Display Items | Display Txn

This listing of claims will replace all prior versions, and listings, of claims in the application:

23/5

LISTING OF CLAIMS

Claim 1. (Currently Amended) A cytochrome P450 3A (CYP3A) inhibitor ~~which~~ wherein said CYP3A inhibitor is a free base or pharmacologically acceptable salt of at least one compound selected from the group consisting of α-naphthoflavone, β-naphthoflavone, ~~apigenin,~~ baicalein, ~~β-myrcene~~, catechin, 3-phenylpropyl acetate, formononetin, ~~gallic acid, hesperetin, hesperidin, isoquercitrin,~~ lauryl alcohol, luteolin, luteolin-7-glycoside, ~~narigin,~~ nordihydroguaiaretic acid, ~~quercitrin,~~ and swertiamarin ~~terpineol, and trans-cinnamaldehyde~~.

Claim 2. (Cancelled)

Claim 3. (Currently Amended) The CYP3A inhibitor according to claim 1, wherein said CYP3A inhibitor is at least one selected from the group consisting of nordihydroguaiaretic acid, (+)-catechin, and lauryl alcohol~~, gallic acid, hesperitin, hesperidin, trans-cinnamaldehyde, β-myrcene and narigin~~.

Claim 4. (Canceled)

Claim 5. (Previously Presented) The CYP3A inhibitor according to claim 1, wherein said CYP3A inhibitor is orally administered to patients.

Claim 6. (Currently Amended) A pharmaceutical composition comprising the ~~The~~ CYP3A inhibitor according to claim 5 and ~~, further comprising~~ at least one pharmaceutically acceptable excipient ~~excipients~~.

Claim 7. (Previously Presented) The CYP3A inhibitor according to claim 1, wherein said CYP3A inhibitor is administered to patients via food or in the form of capsule or tablet.

Claim 8. (Previously Presented) The CYP3A inhibitor according to claim 1, wherein said CYP3A inhibitor is co-administered with a first-pass effect drug.

Claim 9. (Previously Presented) The CYP3A inhibitor according to claim 9, wherein said first-pass effect drug and said CYP3A inhibitor are co-administered orally.

Claim 10. (Previously Presented) The CYP3A inhibitor according to claim 8, wherein said drug is one selected from the group consisting of erythromycin, felodipine, troleandomycin, nifedipine, cyclosporin, FK506, teffenadine, tamoxifen, lidocaine, triazolam, dapsone, diltiazem, lovastatin, simvastatin, quinidine, ethylestradiol, testosterone, midazolam, and alfentanil.

Claim 11. (Previously Presented) The CYP3A inhibitor according to claim 8, wherein said CYP3A inhibitor is catechin, and wherein said first-pass effect drug is simvastatin.

Claim 12. (Previously Presented) The CYP3A inhibitor according to claim 1, wherein said CYP3A inhibitor is orally administered to patients with cancer.

duplicate Q5

Claim 13. (Previously Presented) The CYP3A inhibitor according to claim 12, wherein said CYP3A cancer is intestinal or hepatic cancer.

Claim 14. (Previously Presented) The CYP3A inhibitor according to claim 13, wherein said intestinal cancer is adenocarcinoma.

Claim 15. (Previously Presented) The CYP3A inhibitor according to claim 13, wherein said hepatic cancer is hepatoma.

Claim 16. (Withdrawn) A method for treating patient with intestinal or hepatic cancer comprising orally administering the CYP3A inhibitor according to claim 1 to said patient with intestinal or hepatic cancer.

Claim 17. (Withdrawn) A cytochrome P450 3A (CYP3A) enhancer which is a free base or pharmacologically acceptable salt of at least one compound selected from the group consisting of apigenin, formononetin, and luteolin-7-glycoside.

Claim 18. (Withdrawn) The CYP3A enhancer according to claim 16, wherein said CYP3A enhancer induce the CYP3A enzymatic activity.

Claim 19. (Withdrawn) A method for treating patients with hepatic failure comprising: treating said patients with hepatic failure with a CYP3A enhancer.

Claim 20. (New) A method for prolonging a therapeutic effect of an orally administered drug in a mammal comprising orally administering a cytochrome P450 3A (CYP3A) inhibitor to said mammal;

wherein said orally administered drug is at least one selected from the group consisting of erythromycin, troleandomycin, terfenadine, tamoxifen, lidocaine, triazolam, dapsone, diltiazem, lovastatin, simvastatin, quinidine, midazolam, and alfentanil; and

wherein said CYP3A inhibitor is at least one selected from the group consisting of α-naphthoflavone, β-naphthoflavone, apigenin, baicalein, β-myrcene, catechin, 3-phenylpropyl acetate, formononetin, hesperetin, hesperidin, isoquercitrin, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, quercitrin, swertiamarin, terpineol, and trans-cinnamaldehyde.

Claim 21. (New) The method according to claim 20, wherein said CYP3A inhibitor is at least one selected from the group consisting of α-naphthoflavone, β-naphthoflavone, baicalein, catechin, 3-phenylpropyl acetate, formononetin, lauryl alcohol, luteolin, luteolin-7-glycoside, nordihydroguaiaretic acid, and swertiamarin.

Claim 22. (New) The method according to claim 20, wherein said orally administered drug and said CYP3A inhibitor are orally co-administered to said mammal.

Claim 23. (New) The method according to claim 20, wherein said CYP3A inhibitor is catechin, and wherein said orally administered drug is simvastatin.

Claim 24. (New) A method for treating a patient suffered from intestinal or hepatic cancer comprising orally administering said patient with a cytochrome P450 3A (CYP3A) inhibitor, wherein said CYP3A inhibitor is at least one selected from the group consisting of α-naphthoflavone, β-naphthoflavone, apigenin, baicalein, β-myrcene, catechin, 3-phenylpropyl acetate, formononetin, gallic acid, hesperetin, hesperidin, isoquercitrin, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, quercitrin, swertiamarin, terpineol, and trans-cinnamaldehyde.

12

Claim 25. (New) The method according to claim 25, wherein said CYP3A inhibitor is at least one selected from the group consisting of α-naphthoflavone, β-naphthoflavone, baicalein, catechin, 3-phenylpropyl acetate, formononetin, lauryl alcohol, luteolin, luteolin-7-glycoside, nordihydroguaiaretic acid, and swertiamarin.